CN111643636A - Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof - Google Patents
Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof Download PDFInfo
- Publication number
- CN111643636A CN111643636A CN202010640856.0A CN202010640856A CN111643636A CN 111643636 A CN111643636 A CN 111643636A CN 202010640856 A CN202010640856 A CN 202010640856A CN 111643636 A CN111643636 A CN 111643636A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- liver disease
- endotoxemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,具体涉及一种治疗肝病肠源性内毒素血症的中药颗粒及其制备方法。所述中药颗粒由以下重量份的原料制成:茵陈15‑30份、黄芩10‑20份、赤芍15‑30份、紫草6‑12份、金钱草15‑30份、郁金8‑15份、大黄5‑15份。本发明的中药颗粒配伍合理、精当,符合“君臣佐使”原则,符合肝病肠源性内毒素血症病机,全方共奏解毒化瘀通腑之功效。The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine granule for treating intestinal endotoxemia of liver disease and a preparation method thereof. The traditional Chinese medicine granules are made from the following raw materials in parts by weight: 15-30 parts of Yin Chen, 10-20 parts of Scutellaria baicalensis, 15-30 parts of red peony, 6-12 parts of comfrey, 15-30 parts of goldenseal, 8 parts of turmeric ‑15 servings, 5‑15 servings of rhubarb. The traditional Chinese medicine granules of the present invention have reasonable and precise compatibility, conform to the principle of "the ruler, ministers and assistants" and the pathogenesis of intestinal endotoxemia of liver disease.
Description
技术领域technical field
本发明涉及中药技术领域,具体涉及一种治疗肝病肠源性内毒素血症的中药颗粒及其制备方法。The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine granule for treating intestinal endotoxemia of liver disease and a preparation method thereof.
背景技术Background technique
内毒素是革兰氏阴性细菌细胞壁的外层成分,其主要化学物质并对人体产生毒性作用的成分是脂多糖(LPS)。在急、慢性及重症肝炎、肝硬化等患者中,由于胃肠屏障功能的减弱和/或肝脏单核巨噬细胞系统特别是肝枯否细胞的损伤,肠道菌群微生态失调,往往合并有肠源性内毒素血症(IETM),资料显示,病毒性肝炎患者的35%-65%伴有IETM的发生,重症肝炎患者IETM的出现率为70%-100%,肝硬化则达79%-92%,内毒素对肝脏可产生直接损伤,也可通过激活枯否细胞释放多种细胞因子,如肿瘤坏死因子-α(TNF-α)、白介素-1(IL-1)、白介素-6(IL-6)、转化生长因子-β1(TGF-β1)、血小板活化因子(PAF)等大量细胞因子与炎性递质,使肝脏发生继发性损伤,使肝细胞出现线粒体功能障碍、细胞能量代谢障碍、氧自由基损伤,促使肝病的重症化与慢性化,最终导致肝衰竭。所以寻求干预或阻断内毒素所致肝损害的最佳方法和手段,有效地控制/减轻肝损伤,防止其进一步恶化,是当今中西医防治肝病研究中一个重要课题。Endotoxin is the outer layer component of the cell wall of gram-negative bacteria, and its main chemical substance and the component that has a toxic effect on the human body is lipopolysaccharide (LPS). In patients with acute, chronic and severe hepatitis, liver cirrhosis, etc., due to the weakening of gastrointestinal barrier function and/or the damage of the liver mononuclear macrophage system, especially the liver Kupffer cells, the intestinal flora microecological imbalance is often combined. Intestinal endotoxemia (IETM), data show that 35%-65% of viral hepatitis patients are accompanied by IETM, 70%-100% of severe hepatitis patients, and 79% of patients with liver cirrhosis. %-92%, endotoxin can cause direct damage to the liver, and can also activate Kupffer cells to release a variety of cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin- 6 (IL-6), transforming growth factor-β1 (TGF-β1), platelet activating factor (PAF) and other cytokines and inflammatory mediators, causing secondary damage to the liver, causing mitochondrial dysfunction in liver cells, Cell energy metabolism disorder and oxygen free radical damage promote the aggravation and chronicity of liver disease, eventually leading to liver failure. Therefore, seeking the best methods and means to intervene or block liver damage caused by endotoxin, effectively control/relieve liver damage, and prevent its further deterioration is an important topic in the research on the prevention and treatment of liver diseases by traditional Chinese and Western medicine.
目前临床上针对内毒素血症尚缺乏行之有效的药物,临床上针对内毒素的治疗一般采取综合措施,主要有保肝治疗,使用抗生素进行肠道脱污染,微生态制剂纠正肠道菌群失调,胃肠动力药物改善肠道内容物淤滞,肠内营养等保护肠道黏膜治疗,免疫疗法等,但临床效果并不满意。At present, there is a lack of effective drugs for endotoxemia in clinical practice. Clinical treatment of endotoxin generally adopts comprehensive measures, mainly including liver protection treatment, use of antibiotics for intestinal decontamination, and microecological preparations to correct intestinal flora. Disorders, gastrointestinal motility drugs to improve intestinal content stasis, enteral nutrition and other treatments to protect intestinal mucosa, immunotherapy, etc., but the clinical effect is not satisfactory.
中医学中虽然没有内毒素血症的同义病名,但一般认为中医学的“毒”与现代医学的“内毒素”之间存在着一定相关性,内毒素是中医热毒之邪的重要物质基础之一,肝病内毒素血症相当于中医“热毒证”范畴,热毒瘀互结、滞于肠腑是其基本病机,因此“清热解毒、化瘀通腑”的治法理论上可有助于“热毒”的清除。Although there is no synonymous name for endotoxemia in traditional Chinese medicine, it is generally believed that there is a certain correlation between the "poison" of traditional Chinese medicine and the "endotoxin" of modern medicine. One of the foundations is that endotoxemia of liver disease is equivalent to the category of "heat-toxin syndrome" in traditional Chinese medicine. The mutual accumulation of heat toxin and blood stasis and stagnation in the intestines are its basic pathogenesis. Therefore, the treatment method of "clearing heat and detoxifying, removing blood stasis and dredging the fu-organs" is theoretically It can help to clear the "heat poison".
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种治疗肝病肠源性内毒素血症的中药颗粒及其制备方法,能够有效降低内毒素水平,减少TNF-a、IL-1、IL-6等炎性因子的释放,改善患者临床症状,降低胆红素,减轻肝损伤,有效防止身体各器官进一步损伤。The purpose of the present invention is to provide a traditional Chinese medicine granule for treating liver disease intestinal endotoxemia and a preparation method thereof, which can effectively reduce the level of endotoxin and reduce the release of inflammatory factors such as TNF-a, IL-1, and IL-6. , Improve the clinical symptoms of patients, reduce bilirubin, reduce liver damage, and effectively prevent further damage to various organs of the body.
为实现上述目的,本发明采用如下技术方案:To achieve the above object, the present invention adopts the following technical solutions:
一种治疗肝病肠源性内毒素血症的中药颗粒,由以下质量分的原料制备而成:A traditional Chinese medicine granule for treating liver disease intestinal-derived endotoxemia is prepared from the following raw materials:
茵陈15-30份、黄芩10-20份、赤芍15-30份、紫草6-12份、金钱草15-30份、郁金8-15份、大黄5-15份。15-30 parts of Yin Chen, 10-20 parts of skullcap, 15-30 parts of red peony, 6-12 parts of comfrey, 15-30 parts of money grass, 8-15 parts of turmeric, 5-15 parts of rhubarb.
进一步的,所述中药颗粒的制备方法,包括如下步骤:Further, the preparation method of described Chinese medicine granule, comprises the steps:
S1、按重量份称取茵陈15-30份、黄芩10-20份、赤芍15-30份、紫草6-12份、金钱草15-30份、郁金8-15份、大黄5-15份,将各原料药清洗、烘干;S1, take by weight 15-30 parts of Yin Chen, 10-20 parts of Scutellaria baicalensis, 15-30 parts of red peony, 6-12 parts of comfrey, 15-30 parts of money grass, 8-15 parts of turmeric, 5 parts of rhubarb -15 copies, each API is cleaned and dried;
S2、将烘干的各原料药经超微粉碎,过200目筛,将制得的药粉混合、搅拌均匀,制得混合中药组合物;S2, the dried raw materials are superfinely pulverized, passed through a 200-mesh sieve, and the obtained medicinal powder is mixed and stirred to obtain a mixed traditional Chinese medicine composition;
S3、将中药组合物加水煎煮,浓缩滤液得到浸膏;S3, the Chinese medicine composition is boiled with water, and the concentrated filtrate obtains the extract;
S4、将浸膏与蔗糖、糊精按照1:3:1的质量比混合,搅拌均匀制成软材、制粒、干燥,得中药颗粒成品。S4. Mix the extract with sucrose and dextrin in a mass ratio of 1:3:1, stir evenly to make soft materials, granulate and dry to obtain finished Chinese medicine granules.
本发明中药颗粒各种原料药的药理作用:Pharmacological effects of various raw materials of traditional Chinese medicine granules of the present invention:
茵陈:味苦、辛,性微寒,归脾、胃、肝、胆经,有清利湿热,利胆退黄的功效。用于黄疸尿少,湿温暑湿,湿疮瘙痒。Yin Chen: Bitter, acrid in taste, slightly cold in nature, returns to the spleen, stomach, liver and gallbladder meridians, has the effect of clearing away dampness and heat, promoting gallbladder and relieving jaundice. It is used for jaundice, oliguria, dampness, heat and dampness, and itching of eczema.
黄芩:苦,寒。归肺、胆、脾、胃、大肠、小肠经。清热燥湿,泻火解毒,止血,安胎,降血压。用于湿温、暑温胸闷呕恶,湿热痞满,泻痢,黄疸,肺热咳嗽,高热烦渴,血热吐衄,痈肿疮毒,胎动不安。Scutellaria baicalensis: bitter, cold. Return lung, gallbladder, spleen, stomach, large intestine, small intestine meridian. Clearing away heat and dampness, purging fire and detoxifying, hemostasis, anti-abortion, lowering blood pressure. It is used for damp-heat, heat-warming, chest tightness and nausea, damp-heat fullness, dysentery, jaundice, cough due to lung heat, high fever and polydipsia, blood heat and vomiting, carbuncle, swollen sore and uneasy fetal movement.
紫草:甘、咸,寒,归心、肝经。凉血,活血,解毒透疹。用于血热毒盛,斑疹紫黑,麻疹不透,疮疡,湿疹,水火烫伤。温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡。Comfrey: sweet, salty, cold, returning to the heart and liver meridians. Cooling blood, promoting blood circulation, detoxification and rash. It is used for blood heat toxin, rash purple-black, measles opaque, sores, eczema, water and fire scalds. Warm rash, damp-heat jaundice, purpura, vomiting, epistaxis, hematuria, stranguria, heat constipation, burns, eczema, erysipelas, carbuncle ulcers.
赤芍:味苦,性微寒。归肝经。具有清热凉血,散瘀止痛的功效。用于热人营血,温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,瘾瘕腹痛,跌扑损伤,痈肿疮疡。炒后药性偏于缓和,活血止痛而不伤中,可用于瘀滞疼痛。酒赤芍以活血散瘀力胜,清热凉血作用较弱。多用于闭经或痛经,跌打损伤。Red peony: bitter in taste, slightly cold in nature. Return to the liver meridian. It has the effect of clearing heat and cooling blood, dissipating blood stasis and relieving pain. It is used for warm people to nourish blood, warm toxin to form spots, vomiting blood and epistaxis, red eyes and swelling and pain, liver depression and hypochondrium pain, amenorrhea dysmenorrhea, abdominal pain due to addiction, fall injury, carbuncle, swollen and sore. After frying, the medicinal properties tend to ease, promote blood circulation and relieve pain without injury, and can be used for stasis pain. Wine red peony is better for promoting blood circulation and dissipating blood stasis, but it has a weak effect of clearing heat and cooling blood. Mostly used for amenorrhea or dysmenorrhea, bruises.
金钱草:甘、咸,微寒。归肝、胆、肾、膀胱经。利湿退黄,利尿通淋,解毒消肿。用于湿热黄疸,胆胀胁痛,石淋,热淋,小便涩痛,痈肿疔疮,蛇虫咬伤。Money grass: sweet, salty, slightly cold. Returns liver, gallbladder, kidney, bladder meridian. Dampness and yellowing, diuresis and stranguria, detoxification and swelling. It is used for damp-heat jaundice, gallbladder distention and hypochondral pain, stone stranguria, hot stranguria, astringent urination, carbuncle swollen boils, and snake and insect bites.
郁金:辛、苦,寒。归肝、心、肺经。活血止痛,行气解郁,清心凉血,利胆退黄。用于胸胁刺痛,胸痹心痛,经闭痛经,乳房胀痛,热病神昏,癫痫发狂,血热吐衄,黄疸尿赤。Turmeric: hard, bitter, cold. Returns the liver, heart and lung meridians. Activating blood and relieving pain, promoting Qi and relieving depression, clearing heart and cooling blood, promoting gallbladder and relieving jaundice. It is used for tingling pain in the chest and flank, chest pain and heartache, amenorrhea, dysmenorrhea, breast tenderness, fever, dizziness, epilepsy, epilepsy, vomiting and epistaxis, jaundice and red urine.
大黄:性味:苦,寒。归脾、胃、大肠、肝、心包经。功效:攻积滞;清湿热;泻火;凉血;祛瘀;解毒主治:实热便秘;热结胸痞;湿热泻痢;黄疸;淋病;水肿腹满;小便不利。Rhubarb: Nature and taste: bitter, cold. Return to the spleen, stomach, large intestine, liver, pericardium meridian. Efficacy: attack accumulated stagnation; clear damp-heat; purify fire; cool blood; remove blood stasis; detoxify Indications: constipation due to excess heat;
本发明配方中,茵陈苦寒下降,功专清利湿热毒邪,是为君药;黄芩清热解毒,紫草解毒凉血,助茵陈解毒退黄;两者共为臣药;金钱草清热利胆,除湿退黄;郁金行气活血、凉血逐瘀;赤芍清热凉血祛瘀,助郁金祛湿退黄,郁金功专肝胆二经,能引诸药直达病所,兼起使药之功。佐以大黄泄热除瘀,通利大便;全方共奏解毒化瘀通腑之功效。In the formula of the present invention, Yinchen reduces bitterness and cold, and Gongzhuo clears dampness and heat toxins, so it is the monarch medicine; Scutellaria baicalensis clears heat and detoxifies, and Lithospermum detoxifies and cools blood, and helps Yinchen detoxify and remove jaundice; the two together are the minister medicine; Gallbladder, dehumidification and yellowing; Turmeric activates Qi and activates blood, cools blood and dissipates blood stasis; Chishao clears heat, cools blood and removes stasis, helps Turmeric to remove dampness and remove jaundice. Turmeric works on the two channels of liver and gallbladder. power. It is supplemented with rhubarb to relieve heat and remove blood stasis, and to clear the stool;
本发明的积极有益效果:Positive beneficial effects of the present invention:
1、本发明中药颗粒配伍合理、精当,符合“君臣佐使”原则,符合肝病肠源性内毒素血症病机。1. The traditional Chinese medicine granules of the present invention are reasonable and precise in compatibility, conform to the principle of "jun, minister and assistant", and conform to the pathogenesis of intestinal endotoxemia of liver disease.
2、本发明治疗肝病肠源性内毒素血症的中药颗粒治疗效果显著,总有效率高达76.3%。2. The traditional Chinese medicine granules for treating liver disease and intestinal endotoxemia of the present invention have remarkable therapeutic effect, and the total effective rate is as high as 76.3%.
具体实施方式Detailed ways
下面结合具体实施例对本发明进行详细说明,但不应理解为本发明的限制。如未特殊说明,下述实施例中所用的技术手段为本领域技术人员所熟知的常规手段,下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。The present invention will be described in detail below in conjunction with specific embodiments, but should not be construed as a limitation of the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples can be obtained from commercial sources unless otherwise specified.
实施例1Example 1
一种治疗肝病肠源性内毒素血症的中药颗粒,由以下质量分的原料制备而成:A traditional Chinese medicine granule for treating liver disease intestinal-derived endotoxemia is prepared from the following raw materials:
茵陈15份、黄芩10份、赤芍15份、紫草6份、金钱草15份、郁金8份、大黄5份。15 parts of Yin Chen, 10 parts of skullcap, 15 parts of red peony, 6 parts of comfrey, 15 parts of money grass, 8 parts of turmeric, and 5 parts of rhubarb.
上述中药颗粒的制备方法包括如下步骤:The preparation method of above-mentioned Chinese medicine granule comprises the steps:
S1、按重量份称取茵陈15-30份、黄芩10-20份、赤芍15-30份、紫草6-12份、金钱草15-30份、郁金8-15份、大黄5-15份,将各原料药清洗、烘干;S1, take by weight 15-30 parts of Yin Chen, 10-20 parts of Scutellaria baicalensis, 15-30 parts of red peony, 6-12 parts of comfrey, 15-30 parts of money grass, 8-15 parts of turmeric, 5 parts of rhubarb -15 copies, each API is cleaned and dried;
S2、将烘干的各原料药经超微粉碎,过200目筛,将制得的药粉混合、搅拌均匀,制得混合中药组合物;S2, the dried raw materials are superfinely pulverized, passed through a 200-mesh sieve, and the obtained medicinal powder is mixed and stirred to obtain a mixed traditional Chinese medicine composition;
S3、将中药组合物加水煎煮,浓缩滤液得到浸膏;S3, the Chinese medicine composition is boiled with water, and the concentrated filtrate obtains the extract;
S4、将浸膏与蔗糖、糊精按照1:3:1的质量比混合,搅拌均匀制成软材、制粒、干燥,得中药颗粒成品。S4. Mix the extract with sucrose and dextrin in a mass ratio of 1:3:1, stir evenly to make soft materials, granulate and dry to obtain finished Chinese medicine granules.
实施例2Example 2
一种治疗肝病肠源性内毒素血症的中药颗粒,由以下质量分的原料制备而成:A traditional Chinese medicine granule for treating liver disease intestinal-derived endotoxemia is prepared from the following raw materials:
茵陈20份、黄芩15份、赤芍25份、紫草10份、金钱草20份、郁金12份、大黄9份。20 parts of Yin Chen, 15 parts of skullcap, 25 parts of red peony, 10 parts of comfrey, 20 parts of money grass, 12 parts of turmeric, and 9 parts of rhubarb.
本实施例所述中药颗粒的制备方法同实施例1。The preparation method of the traditional Chinese medicine granules described in this example is the same as that in Example 1.
实施例3Example 3
一种治疗肝病肠源性内毒素血症的中药颗粒,由以下质量分的原料制备而成:A traditional Chinese medicine granule for treating liver disease intestinal-derived endotoxemia is prepared from the following raw materials:
茵陈30份、黄芩20份、赤芍30份、紫草12份、金钱草30份、郁金15份、大黄15份。30 parts of Yin Chen, 20 parts of skullcap, 30 parts of red peony, 12 parts of comfrey, 30 parts of money grass, 15 parts of turmeric, 15 parts of rhubarb.
本实施例所述中药颗粒的制备方法同实施例1。The preparation method of the traditional Chinese medicine granules described in this example is the same as that in Example 1.
实施例4Example 4
一种治疗肝病肠源性内毒素血症的中药颗粒,由以下质量分的原料制备而成:A traditional Chinese medicine granule for treating liver disease intestinal-derived endotoxemia is prepared from the following raw materials:
茵陈30份、黄芩15份、赤芍30份、紫草12份、金钱草30份、郁金15份、大黄10份。30 parts of Yin Chen, 15 parts of skullcap, 30 parts of red peony, 12 parts of comfrey, 30 parts of money grass, 15 parts of turmeric, 10 parts of rhubarb.
本实施例所述中药颗粒的制备方法同实施例1。The preparation method of the traditional Chinese medicine granules described in this example is the same as that in Example 1.
临床试验Clinical Trials
1、诊断标准1. Diagnostic criteria
诊断均符合2012年版肝衰竭诊治指南中亚急性或慢加急性肝衰竭西医诊断标准,且满足20%≤PTA≤40%、未合并上消化道出血及肝性脑病II期及以上、中医辨证无明显寒湿、阳虚之象者(参照中医内科黄疸辨证分型),同时排除有糖尿病、内分泌病、肿瘤,风湿免疫系统疾病者,严重的心、脑、肾等其他系统疾病和精神障碍者,近期服用中西药免疫制剂者,孕妇和哺乳期妇女以及对药物过敏者。All patients were diagnosed in accordance with the western medicine diagnostic criteria for subacute or acute-on-chronic liver failure in the 2012 edition of the liver failure diagnosis and treatment guidelines, and 20%≤PTA≤40%, no upper gastrointestinal bleeding and hepatic encephalopathy stage II or above, and no TCM syndrome differentiation. Those with obvious signs of cold-dampness and yang deficiency (refer to TCM internal medicine jaundice syndrome differentiation and classification), and those with diabetes, endocrine diseases, tumors, rheumatic immune system diseases, serious heart, brain, kidney and other system diseases and mental disorders are excluded. , Those who have recently taken Chinese and Western medicine immune preparations, pregnant and lactating women, and those who are allergic to drugs.
2、临床资料2. Clinical data
将研究对象随机分为试验组与对照组,各组34例。试验组的男性患者23例,女性8例,平均年龄(46.5±8.7)岁;对照组的的男性患者21例,女性8例,平均年龄(45.8±6.8)岁。两组患者一般资料比较差异均无统计学意义(P>0.05),具有可比性。The subjects were randomly divided into the experimental group and the control group, with 34 cases in each group. The experimental group included 23 male patients and 8 female patients with an average age of (46.5±8.7) years; the control group included 21 male patients and 8 female patients with an average age of (45.8±6.8) years. There was no significant difference in general data between the two groups (P>0.05), which was comparable.
3、治疗方案3. Treatment plan
两组患者入院后均给予常规西医综合治疗,包括一般治疗、针对病因及发病机制的治疗、并发症治疗以及单纯血浆置换(3日一行,每位患者行3-4次)。试验组在上述基础上加用本发明的中药颗粒,2次/日,每次一包,每包5g,冲服。疗程均为30天。After admission, both groups of patients were given routine western medicine comprehensive treatment, including general treatment, treatment for etiology and pathogenesis, treatment of complications, and simple plasma exchange (one trip for 3 days, 3-4 times for each patient). The experimental group added the Chinese medicine granules of the present invention on the basis of the above, 2 times a day, one packet each time, 5 g per packet, and blistered. The course of treatment is 30 days.
4、统计学处理4. Statistical processing
统计学分析采用SPSS19.0统计软件。计量资料用均数±标准差(±s)表示。符合正态分布的计量资料用t检验,计数资料中分类有序资料采用秩和检验,分类无序资料采用χ2检验。P<0.05有统计学意义。Statistical analysis was performed using SPSS 19.0 statistical software. Measurement data were expressed as mean±standard deviation (±s). The measurement data conforming to the normal distribution was tested by t test, the categorical and ordered data in the enumeration data was by the rank sum test, and the categorically disordered data was by the χ2 test. P<0.05 was statistically significant.
5、结果5. Results
1)肝功能指标比较:治疗后两组TBIL、DBIL水平较治疗前均有所降低,且试验组明显低于对照组,差异具有统计学意义(P<0.05);治疗后试验组的CHE、ALB值均略高于对照组,但差异无统计学意义(P>0.05);两组患者治疗后血清ALT、AST、ALP、GGT水平较治疗前均明显降低,且试验组均低于对照组,但差距无统计学意义(P>0.05)。见表1。1) Comparison of liver function indexes: after treatment, the levels of TBIL and DBIL in the two groups were decreased compared with those before treatment, and the experimental group was significantly lower than the control group, and the difference was statistically significant (P<0.05). The ALB values were slightly higher than those in the control group, but the difference was not statistically significant (P>0.05). The serum ALT, AST, ALP, and GGT levels of the two groups of patients after treatment were significantly lower than those before treatment, and the experimental group was lower than the control group. , but the difference was not statistically significant (P>0.05). See Table 1.
表1试验组和对照组治疗前后肝功能指标比较 Table 1 Comparison of liver function indexes before and after treatment between the experimental group and the control group
注:与治疗前相比,☆P<0.05;与试验组相比,△P<0.05。Note: Compared with before treatment, ☆P<0.05; compared with experimental group, △P<0.05.
2)PTA及ET指标比较:治疗后两组的PTA均升高,且试验组的PTA值明显高于对照组,差异具有统计学意义(P<0.05)。见表2。2) Comparison of PTA and ET indexes: After treatment, the PTA of both groups increased, and the PTA value of the experimental group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). See Table 2.
表2试验组和对照组治疗前后PTA、ET指标比较 Table 2 Comparison of PTA and ET indexes between the experimental group and the control group before and after treatment
注:与治疗前相比,☆P<0.05;与试验组相比,△P<0.05。Note: Compared with before treatment, ☆P<0.05; compared with experimental group, △P<0.05.
4)临床疗效比较:试验组和对照组的治疗总有效率分别为76.3%和61.6%,对两组的治疗效果进行秩和检验显示试验组和对照组的临床疗效差异具有统计学意义(P<0.05),试验组优于对照组。见表3。4) Comparison of clinical efficacy: the total effective rates of the experimental group and the control group were 76.3% and 61.6%, respectively. The rank sum test of the therapeutic effects of the two groups showed that the clinical efficacy difference between the experimental group and the control group was statistically significant (P <0.05), the experimental group was better than the control group. See Table 3.
表3试验组和对照组治疗前后临床疗效比较[例(%)]Table 3 Comparison of clinical efficacy before and after treatment between the experimental group and the control group [case (%)]
典型病例Typical cases
1、李某某,男,某厂职工,39岁。2016年7月以身目黄染、腹胀乏力为主诉入院。患者乙肝病史10余年,3年前开始服用恩替卡韦片抗病毒治疗,半年前自行停用抗病毒药,近半月来自觉乏力,纳差,并出现皮肤及巩膜黄染,并逐渐加重。入院查肝功能:ALT 298U/L,AST387U/L、ALP 151U/L、GGT 110U/L、TBIL 348.7umol/l、DBIL 234.5umol/l,ET:0.72EU/L,PTA:30.5%,HBV-DNA:3.82×105IU/ML,上腹部CT示:肝硬化,脾大,腹水。治疗上给予抗病毒、保肝抗炎退黄、营养支持等措施,并口服实施例1制备的中药颗粒,经综合治疗,患者乏力腹胀、纳差症状明显改善,疗程结束时复查肝功:ALT 79U/L,AST 86U/L、ALP 133U/L、GGT102U/L、TBIL 121.6umol/l、DBIL 58.8umol/l,ET:0.22EU/L,PTA:41.6%,后继续给予中西医结合治疗,患者病情好转出院,病情稳定。1. Li Moumou, male, a factory worker, 39 years old. In July 2016, he was admitted to the hospital with the main complaints of yellow eyes, bloating and fatigue. The patient has a history of hepatitis B for more than 10 years. He started taking entecavir antiviral therapy 3 years ago, and stopped antiviral drugs half a year ago. In the past half month, he felt fatigue, anorexia, and yellowing of the skin and sclera, which gradually worsened. Liver function examination on admission: ALT 298U/L, AST387U/L, ALP 151U/L, GGT 110U/L, TBIL 348.7umol/l, DBIL 234.5umol/l, ET: 0.72EU/L, PTA: 30.5%, HBV- DNA: 3.82×10 5 IU/ML, upper abdominal CT showed: liver cirrhosis, splenomegaly, ascites. In the treatment, measures such as anti-virus, liver protection, anti-inflammation and anti-yellowing, and nutritional support were given, and the traditional Chinese medicine granules prepared in Example 1 were taken orally. 79U/L, AST 86U/L, ALP 133U/L, GGT102U/L, TBIL 121.6umol/l, DBIL 58.8umol/l, ET: 0.22EU/L, PTA: 41.6%, and then continued to give integrative medicine, The patient's condition improved and was discharged from hospital in stable condition.
2、张某,男,农民,54岁,2017年9月年因身目黄染就诊。患者既往长期大量饮酒史,日乙醇摄入量50-100g,2年前在外院诊断为肝硬化,但患者并未戒酒。入院后查肝功:ALT:225U/L,AST 487U/L、ALP 291U/L、GGT 562U/L、TBIL 278.7umol/l、DBIL 138.5umol/l,ET:0.69EU/L,PTA:32.5%,上腹部CT提示肝硬化,治疗上给予保肝、退黄、营养支持措施,同时予中药颗粒口服,期间患者症状逐渐改善,至疗程结束时ALT:87U/L,AST 132U/L、ALP151U/L、GGT 342U/L、TBIL 89.3umol/l、DBIL 68.5umol/l,ET:0.29EU/L,PTA:43.7%,出院后继续药物治疗,随访至今病情稳定。2. Zhang Mou, male, farmer, 54 years old, went to see a doctor in September 2017 because of yellow eyes and body. The patient has a long history of heavy drinking, with a daily ethanol intake of 50-100 g. He was diagnosed with liver cirrhosis in a foreign hospital two years ago, but the patient has not stopped drinking. Liver function examination after admission: ALT: 225U/L, AST 487U/L, ALP 291U/L, GGT 562U/L, TBIL 278.7umol/l, DBIL 138.5umol/l, ET: 0.69EU/L, PTA: 32.5% , CT of the upper abdomen showed liver cirrhosis. In the treatment, hepatoprotective, jaundice, and nutritional support measures were given. At the same time, traditional Chinese medicine granules were given orally. During the period, the patient's symptoms gradually improved. At the end of the course of treatment, ALT: 87U/L, AST 132U/L, ALP151U/L L, GGT 342U/L, TBIL 89.3umol/l, DBIL 68.5umol/l, ET: 0.29EU/L, PTA: 43.7%, continued drug treatment after discharge, and her condition is stable so far during follow-up.
需要说明的是,本发明权利要求书中涉及数值范围时,应理解为每个数值范围的两个端点以及两个端点之间任何一个数值均可选用,为了防止赘述,本发明描述了优选的实施例。It should be noted that when a numerical range is involved in the claims of the present invention, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. In order to prevent repetition, the present invention describes the preferred Example.
尽管已描述了本发明的优选实施例,但本领域内的技术人员一旦得知了基本创造性概念,则可对这些实施例作出另外的变更和修改。所以,所附权利要求意欲解释为包括优选实施例以及落入本发明范围的所有变更和修改。Although preferred embodiments of the present invention have been described, additional changes and modifications to these embodiments may occur to those skilled in the art once the basic inventive concepts are known. Therefore, the appended claims are intended to be construed to include the preferred embodiment and all changes and modifications that fall within the scope of the present invention.
显然,本领域的技术人员可以对本发明进行各种改动和变型而不脱离本发明的精神和范围。这样,倘若本发明的这些修改和变型属于本发明权利要求及其等同技术的范围之内,则本发明也意图包含这些改动和变型在内。It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention. Thus, provided that these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010640856.0A CN111643636A (en) | 2020-07-06 | 2020-07-06 | Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010640856.0A CN111643636A (en) | 2020-07-06 | 2020-07-06 | Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111643636A true CN111643636A (en) | 2020-09-11 |
Family
ID=72344057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010640856.0A Pending CN111643636A (en) | 2020-07-06 | 2020-07-06 | Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643636A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114460159A (en) * | 2022-02-17 | 2022-05-10 | 河南中医药大学 | ALP activity detection kit based on photo-ATRP signal amplification strategy and use method thereof |
CN117653706A (en) * | 2023-12-25 | 2024-03-08 | 江苏省中医院 | Formula for treating cholestatic jaundice, preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689612A (en) * | 2004-04-29 | 2005-11-02 | 广东红珊瑚药业有限公司 | Liver disease treating particle and its production method |
CN101675987A (en) * | 2008-09-18 | 2010-03-24 | 吴志强 | Traditional Chinese medicine concentrated solution for treating liver and gall stone |
CN102847068A (en) * | 2012-08-31 | 2013-01-02 | 李承平 | Capillary wormwood herb tablets with function of heat clearing |
CN103007186A (en) * | 2012-10-16 | 2013-04-03 | 义乌市民间中草药肝病防治研究所 | Chinese medicinal formulae used for treating increase of jaundice |
-
2020
- 2020-07-06 CN CN202010640856.0A patent/CN111643636A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1689612A (en) * | 2004-04-29 | 2005-11-02 | 广东红珊瑚药业有限公司 | Liver disease treating particle and its production method |
CN101675987A (en) * | 2008-09-18 | 2010-03-24 | 吴志强 | Traditional Chinese medicine concentrated solution for treating liver and gall stone |
CN102847068A (en) * | 2012-08-31 | 2013-01-02 | 李承平 | Capillary wormwood herb tablets with function of heat clearing |
CN103007186A (en) * | 2012-10-16 | 2013-04-03 | 义乌市民间中草药肝病防治研究所 | Chinese medicinal formulae used for treating increase of jaundice |
Non-Patent Citations (6)
Title |
---|
刘巧红: "解毒化瘀通腑颗粒治疗亚急性和慢加急性肝衰竭患者的疗效及其对 TLR4 /NF-κB 炎性通路的影响", 《中西医结合肝病杂志》 * |
刘江凯等: "解毒化瘀通腑方对酒精性肝硬化患者内毒素及炎性因子的影响", 《中华中医药杂志》 * |
张建文: "退黄合剂治疗乙型肝炎伴胆汁淤滞38例", 《中国民间疗法》 * |
江志华: "退黄合剂联合人工肝血浆置换治疗重型肝炎20例", 《河南中医》 * |
罗佳佳等: "重型肝炎肠源性内毒素血症的中医药治法初探", 《继续医学教育》 * |
马素平: "退黄合剂治疗黄疸型病毒性肝炎56例", 《陕西中医》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114460159A (en) * | 2022-02-17 | 2022-05-10 | 河南中医药大学 | ALP activity detection kit based on photo-ATRP signal amplification strategy and use method thereof |
CN114460159B (en) * | 2022-02-17 | 2023-11-03 | 河南中医药大学 | ALP activity detection kit based on photo-ATRP signal amplification strategy and its use method |
CN117653706A (en) * | 2023-12-25 | 2024-03-08 | 江苏省中医院 | Formula for treating cholestatic jaundice, preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111643636A (en) | Traditional Chinese medicine granules for treating liver disease enterogenic endotoxemia and preparation method thereof | |
CN102727758A (en) | Traditional Chinese medicine enema for treating ulcerative colitis | |
CN113616714A (en) | High-selenium anti-HPV (human papillomavirus) biological protein gel dressing and preparation method thereof | |
CN103800842A (en) | Traditional Chinese medicine composition for treating carcinoma of urinary bladder | |
CN103055218B (en) | Traditional Chinese medicine composition for treating neonatal jaundice and preparation method thereof | |
CN103585341B (en) | Traditional Chinese medicine composition for treating acute pancreatitis and preparation method of composition | |
CN112535709A (en) | A Chinese medicinal composition for treating colitis | |
CN103285106A (en) | Traditional Chinese medicinal composition for treating intestinal mucosa damage and preparation method and application thereof | |
CN111228367B (en) | Traditional Chinese medicine external lotion for treating infantile anaphylactoid purpura and preparation method thereof | |
CN100381142C (en) | A medicine for treating hepatitis | |
CN113648349B (en) | A topical Chinese medicinal composition for preventing and treating rheumatism and pyretic arthralgia, and its preparation method | |
CN112972559B (en) | Traditional Chinese medicine composition and traditional Chinese medicine mixture for treating bone and soft tissue suppurative inflammation | |
CN105287955A (en) | Traditional Chinese medicine preparation used for treating jaundice and preparation method | |
CN114748562B (en) | Traditional Chinese medicine composition for adjuvant therapy of cancerous ascites as well as preparation method and application thereof | |
CN110772568A (en) | Traditional Chinese medicine composition for treating radiation enteritis and preparation method thereof | |
CN104189649A (en) | Traditional Chinese medicine composition for treating recurrent genital herpes | |
CN108815458A (en) | A kind of drug for treating Severe Acute Pancreatitis SAP early stage | |
CN113633748B (en) | Medicine for treating spontaneous bacterial peritonitis damp-heat stasis syndrome of liver cirrhosis and preparation method thereof | |
CN117180361B (en) | Traditional Chinese medicine for treating spleen deficiency and qi stagnation combined with damp-heat type ulcerative colitis | |
CN102784206B (en) | Niweikang and preparation method thereof | |
CN106491974B (en) | Traditional Chinese medicine composition and traditional Chinese medicine decoction for treating enteroparalysis | |
CN119424592A (en) | Traditional Chinese medicine composition for treating phlegm-stasis-blocking type pulmonary nodules and preparation method thereof | |
CN116407594A (en) | Traditional Chinese medicine composition for treating thyroid cyst and preparation method thereof | |
CN105194429A (en) | Traditional Chinese medicine for treating bronchial asthma | |
CN119818633A (en) | Traditional Chinese medicine composition for treating pulmonary nodules, preparation and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |